March 2017 Meeting Announcement, Delaware Valley Mass Spectrometry Discussion Group
- Topic: "The Expanding Role of Quantitative Bioanalysis to Support Drug Discovery and Development - increasingly complex multiple component methods for comprehensive data sets
- Speaker:Timothy V. Olah, Bristol-Myers Squibb
- Date: Monday, March 13, 2017. 6:00 PM
- Please RSVP to email@example.com by Thursday March 9.
- Time: Social Hour: 6:00 PM.
Talk: 7:00 PM.
- Place: Department of Chemistry, Villanova University (Mendel Hall 154)
Timothy V. Olah, Ph.D. Bristol-Myers Squibb:
Dr. Olah is the Group Director of Bioanalytical Research at Bristol-Myers Squibb where his team's research centers on the development of comprehensive multiple component bioanalytical methods to measure all types of drug modalities and endogenous proteins and biomarkers in biological fluids using advanced sample enrichment techniques and liquid chromatography mass spectrometry detection. These methods support all drug discovery programs at BMS and the BMS-Biocon-Research-Center (BBRC) in Bangalore, India.
He is a graduate of Princeton University (BA Chemistry) and the University of Pennsylvania (Ph.D. Biological Chemistry). Dr. Olah joined the Department of Drug Metabolism at Merck Research Laboratories in West Point, PA and helped establish the first LCMS-based Bioanalytical group under the late Dr. John D. Gilbert. He moved to the DuPont Pharmaceuticals Company in 2000. Following the purchase of DuPont Pharmaceuticals by Bristol-Myers Squibb in 2001, he was appointed the Director of Bioanalytical Research. Dr. Olah has over 95 publications and has presented at numerous international universities and conferences throughout his career.
Please send any comments, corrections, or suggestions to
This page has been accessed
times since 9/15 /96 .
Last Updated 2/21/2017